| Literature DB >> 22594526 |
Yoshio Shirai1, Jun Sakata, Toshifumi Wakai, Taku Ohashi, Yoichi Ajioka, Katsuyoshi Hatakeyama.
Abstract
UNLABELLED: AEntities:
Mesh:
Year: 2012 PMID: 22594526 PMCID: PMC3532237 DOI: 10.1186/1477-7819-10-87
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Radical resection procedures for 135 patients with gallbladder cancer
| Extended cholecystectomy | |
| C + WR + BD + N* | 53 |
| C + WR + N | 23 |
| C† + N | 11 |
| C† + BD + N | 6 |
| More extensive resection | |
| C + ERH + BD + N | 14 |
| C + Central hepatectomy‡ + BD + N | 3 |
| C + ELH + BD + N | 1 |
| C + Right trisectionectomy + BD + N | 1 |
| C + WR + PD + N | 15 |
| C + ERH + PD + N | 6 |
| C + ERH + PPPD + N | 2 |
*Designated as ‘extended’ radical cholecystectomy at our department since 1982 [11,13,14].
†Cholecystectomy with full-thickness dissection: cholecystectomy combined with removal of the cystic plate.
‡Defined as removal of Couinaud segments IV, V, and VIII.
C, cholecystectomy; WR, wedge resection of the gallbladder fossa; BD, resection of the extrahepatic bile duct; N, regional lymphadenectomy; ERH, extended right hepatectomy (right hepatectomy extended to an inferior portion of Couinaud segment 4); ELH, extended left hepatectomy (left hepatectomy extended to an inferior portion of right anterior section); PD, Whipple pancreaticoduodenectomy; PPPD, pylorus-preserving pancreaticoduodenectomy.
Factors influencing long-term survival after resection in 135 patients with gallbladder cancer
| Age (years) | | | | 0.123 | | |
| ≤70 | 86 | 66 | 63 | | | |
| >70 | 49 | 52 | 49 | | | |
| Sex | | | | 0.652 | | |
| Male | 41 | 66 | 61 | | | |
| Female | 94 | 59 | 57 | | | |
| Gallstone | | | | 0.028 | | 0.003 |
| Absent | 73 | 52 | 50 | | 2.801 (1.435-5.470) | |
| Present | 62 | 72 | 68 | | 1.000 | |
| Type of radical resection | | | | <0.001 | | |
| Extended cholecystectomy | 93 | 77 | 76 | | | |
| Major hepatectomy | 19 | 9 | 9 | | | |
| Pancreaticoduodenectomy | 15 | 45 | 28 | | | |
| Major hepatectomy with pancreaticoduodenectomy | 8 | 25 | 25 | | | |
| Timing of radical resection | | | | 0.007 | | |
| Initial radical resection | 111 | 56 | 52 | | | |
| Radical second resection | 24 | 86 | 86 | | | |
| Adjuvant chemotherapy | | | | 0.093 | | |
| Absent | 85 | 57 | 52 | | | |
| Present | 50 | 68 | 68 | | | |
| Size of the primary tumor (mm) | | | | 0.869 | | |
| ≤60 | 68 | 61 | 59 | | | |
| >60 | 67 | 61 | 57 | | | |
| pT classification* | | | | <0.001 | | 0.005 |
| pT1 plus pT2 | 80 | 87 | 85 | | 1.000 | |
| pT3 plus pT4 | 55 | 21 | 15 | | 3.145 (1.412-6.948) | |
| Total lymph node count (TLNC) | | | | 0.102 | | |
| ≤16 | 76 | 66 | 66 | | | |
| >16 | 59 | 55 | 48 | | | |
| Location of positive lymph nodes* | | | | <0.001 | | |
| pN0 | 76 | 80 | 80 | | | |
| pN1 | 24 | 57 | 46 | | | |
| pN2 | 35 | 23 | 20 | | | |
| Number of positive lymph nodes | | | | <0.001 | | 0.004 |
| 0 | 76 | 80 | 80 | | 1.000 | |
| 1-3 | 39 | 51 | 41 | | 1.640 (0.784-3.431) | |
| ≥4 | 20 | 10 | 10 | | 4.997 (1.905-13.003) | |
| Lymph node ratio (LNR; %) | | | | <0.001 | | |
| 0 | 76 | 80 | 80 | | | |
| 0-10 | 22 | 60 | 49 | | | |
| >10 | 37 | 24 | 20 | | | |
| pM classification* | | | | <0.001 | | 0.014 |
| pM0 | 109 | 72 | 69 | | 1.000 | |
| pM1 | 26† | 13 | 7 | | 2.260 (1.178-4.337) | |
| Histological type* | | | | <0.001 | | |
| Adenocarcinoma | 114 | 66 | 64 | | | |
| Others | 21 | 32 | 26 | | | |
| Histological grade* | | | | 0.001 | | <0.001 |
| G1 plus G2 | 96 | 68 | 67 | | 1.000 | |
| G3 plus G4 | 39 | 42 | 34 | | 3.472 (1.766-6.828) | |
| Lymphatic vessel invasion (L)* | | | | <0.001 | | |
| L0 | 57 | 85 | 83 | | | |
| L1 | 78 | 44 | 41 | | | |
| Venous invasion (V)* | | | | <0.001 | | 0.007 |
| V0 | 74 | 78 | 76 | | 1.000 | |
| V1 | 61 | 41 | 37 | | 2.445 (1.279-4.673) | |
| Perineural invasion | | | | <0.001 | | |
| Absent | 88 | 77 | 74 | | | |
| Present | 47 | 29 | 26 | | | |
| Residual tumor status* | | | | <0.001 | | 0.003 |
| R0 | 121 | 67 | 64 | | 1.000 | |
| R1 plus R2 | 14 | 0 | 0 | 3.306 (1.519-7.195) | ||
*According to the AJCC cancer staging manual (7th edition) [8].
†Includes 13 with paraaortic nodal disease.
CI, confidence interval; pT classification, pathological primary tumor classification; pN classification, pathological regional lymph nodes classification; pM classification, pathological distant metastasis classification; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated; L0, no lymphatic vessel invasion; L1, lymphatic vessel invasion; V0, no venous invasion; V1, microscopic venous invasion; R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor.
Analysis of the number of positive lymph nodes using the Cox proportional hazards regression model
| 0, ≥1 | 5.217 | 0.022 |
| 0, 1, ≥2 | 7.832 | 0.020 |
| 0, 1–2, ≥3 | 7.611 | 0.022 |
| 0, 1–3, ≥4 | 13.234 | 0.001 |
| 0, 1–4, ≥5 | 7.213 | 0.027 |
| 0, 1–5, ≥6 | 5.275 | 0.072 |
| 0, 1–6, ≥7 | 5.275 | 0.072 |
| 0, 1–7, ≥8 | 5.233 | 0.073 |
Analysis of the lymph node ratio (LNR) calculated by the Cox proportional hazards regression model
| 0, 0–5, >5 | 7.006 | 0.030 |
| 0, 0–10, >10 | 7.547 | 0.023 |
| 0, 0–15, >15 | 6.516 | 0.038 |
| 0, 0–20, >20 | 6.731 | 0.035 |
| 0, 0–25, >25 | 6.881 | 0.032 |
| 0, 0–30, >30 | 6.212 | 0.045 |
| 0, 0–35, >35 | 6.844 | 0.033 |
| 0, 0–40, >40 | 5.938 | 0.051 |
Figure 1 Kaplan-Meier disease-specific survival estimates according to the presence or absence of regional nodal disease. The median survival time was not reached with a 5-year survival rate of 80% in patients without nodal disease, whereas the median survival time was 24 months with a 5-year survival rate of 37% in patients with nodal disease ( P < 0.001).
Figure 2 Kaplan-Meier disease-specific survival estimates according to the location of positive regional lymph nodes. The median survival time was not reached with a 5-year survival rate of 80% in patients without nodal disease (pN0). The median survival time was 74 months with a 5-year survival rate of 57% in patients with pN1 disease. The median survival time was 13 months with a 5-year survival rate of 23% in patients with pN2 disease. The survival post-resection differed significantly among the groups ( P < 0.001).
Figure 3 Kaplan-Meier disease-specific survival estimates according to the number of positive regional lymph nodes. The median survival time was not reached with a 5-year survival rate of 80% in patients without nodal disease. The median survival time was 63 months with a 5-year survival rate of 51% in patients with 1 to 3 positive nodes. The median survival time was 11 months with a 5-year survival rate of 10% in patients with ≥4 positive nodes. The survival post-resection differed significantly among the groups ( P < 0.001).
Figure 4Kaplan-Meier disease-specific survival estimates according to the lymph node ratio (LNR) of regional lymph nodes. The median survival time was not reached with a 5-year survival rate of 80% in patients without nodal disease (LNR of 0%). The median survival time was 74 months with a 5-year survival rate of 60% in patients with a LNR of 0 to 10%. The median survival time was 15 months with a 5-year survival rate of 24% in patients with a LNR of > 10%. The survival post-resection differed significantly among the groups ( P < 0.001).